Promotion, prediction and prevention of progression of nephropathy in type 1 diabetes mellitus

Diabetic Medicine

Volumn 15, Issue 11, 1998, Pages 900-919

  Rossing, P ^a  

^a STENO DIABETES CENTER   (Denmark)

Author keywords

Antihypertensive therapy; Prognosis; Survival; Type 1 DM diabetic nephropathy

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

ANTIHYPERTENSIVE THERAPY; CARDIOVASCULAR RISK; DIABETIC NEPHROPATHY; DIET THERAPY; DISEASE COURSE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MORBIDITY; MORTALITY; PROGNOSIS; REVIEW; SURVIVAL;

ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; DIABETIC ANGIOPATHIES; DIABETIC NEPHROPATHIES; DIET, PROTEIN-RESTRICTED; DISEASE PROGRESSION; HUMANS; HYPERTENSION; INCIDENCE; PROGNOSIS; PROTEINURIA;

EID: 0031792760     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9136(1998110)15:11<900::AID-DIA709>3.0.CO;2-0     Document Type: Review

References (189)

1. Andersen AR, Christiansen JS, Andersen JK, Kreiner S, Deckert T. Diabetic nephropathy in Type 1 (insulin-dependent) diabetes: an epidemiological study. Diabetologia 1983; 25: 496-501.
2. Krolewski AS, Warram JH, Christlieb AR, Busick EJ, Kahn CR. The changing natural history of nephropathy in Type 1 diabetes. Am J Med 1985; 78: 785-794.
3. Kofoed-Enevoldsen A, Borch-Johnsen K, Kreiner S, Nerup I, Deckert T. Declining incidence of persistent proteinuria in type 1 (insulin-dependent) diabetic patients in Denmark. Diabetes 1987; 36: 205-209.
4. Parving H-H, Smidt UM, Friisberg B, Bonnevie-Nielsen V, Andersen AR. A prospective study of glomerular filtration rale and arterial blood pressure in insulin-dependent diabetics with diabetic nephropathy. Diabetologia 1981; 20: 457-461.
5. Eggers PW. Effect of transplantation on the Medicare end-stage renal disease program. N Engl Med 1988; 318: 223-229.
6. Striker GE, Agodoa EE, Held P, Doi T, Conti FG, Striker LJ. Kidney disease of diabetes mellitus (diabetic nephropathy): perspectives in the United States. J Diabet Complications 1992; 5: 51-52.
7. Mogensen CE. Long-term antihypertensive treatment inhibiting progression of diabetic nephropathy. Br Med J 1982; 285: 685-688.
8. Parving H-H, Andersen AR, Smidt UM, Svendsen PA. Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy. Lancet 1983; i: 1175-1179.
9. Deckert T, Poulsen JE, Larsen M. Prognosis of diabetics with diabetes onset before the age of thirty-one. I. Survival, causes of death and complications. Diabetologia 1978; 14: 363-70.
10. Borch-Johnsen K, Kreiner S. Proteinuria: value as predictor of cardiovascular mortality in insulin dependent diabetes mellitus. Br Med J 1987; 294: 1651-1654.
11. Mogensen CE, Chachati A, Christensen CK, Close CF, Deckert T, Hommel E, et al. Microalbuminuria: an early marker of renal involvement in diabetes. Uremia Invest 1985; 9: 85-95.
12. Mogensen CE. Angiotensin converting enzyme inhibitors and diabetic nephropathy. Br Med J 1992; 304: 327-328.
13. Levey AS, Gassman J, Hall PM, Walker WG, the Modification of Diet in Renal Disease Study group. Assessing the progression of renal disease in clinical studies: of follow-up and regression to the mean. J Am Soc Nephrol 1991; 1: 1087-1094.
14. Shemesh O, Golbetz HV, Kriss JP, Myers BD. Limitations of creatinine as a filtration marker in glomerulopathic patients. Kidney Int 1985; 28: 830-838.
15. Rossing P, Astrup A-S, Smidt UM, Parving H-H. Monitoring kidney function in diabetic nephropathy. Diabetologia 1994; 37: 708-712.
16. Glassock RJ, Hirschman GH, Striker GE. Workshop on the use of renal biopsy in research on diabetic nephropathy: a summary report. Am J Kidney Dis 1991; 18: 589-592.
17. Bangstad H-J, østerby R, Dahl-Jørgensen K, Berg K, Hartmann A, Hanssen KF. Improvement of blood glucose control in IDDM patients retards the progression of morphological changes in early diabetic nephropathy. Diabetologia 1994; 37: 483-490.
18. Schmidt-Nielsen B. August and Marie Krogh - Lives in Science. New York: Oxford University Press, 1996.
19. Bojestig M, Arnqvist HJ, Hermansson G, Karlberg B, Ludvigsson J. Declining incidence of nephropathy in insulin-dependent diabetes mellitus. N Engl J Med 1994; 330: 15-18.
20. Parving H-H, Hommel E, Mathiesen ER, Skøtt P, Edsberg B, Bahnsen M, et al. Prevalence of microalbuminuria, arterial hypertension, retinopathy and neuropathy in patients with insulin-dependent diabetes. Br Med J 1988; 296: 156-160.
21. Rossing P, Rossing K, Jacobsen P, Parving H-H. Unchanged incidence of diabetic nephropathy in IDDM patients. Diabetes 1995; 44: 739-743.
22. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986.
23. 1c values between laboratories of diabetic complications studies (Abstract) Diabetologia 1995; 38: A184.
24. Rudberg S, Ullman E, Dahlquist G. Relationship between early metabolic control and the development of microalbuminuria - a longitudinal study in children with type 1 (insulin-dependent) diabetes mellitus. Diabetologia 1993; 36: 1309-1314.
25. Wang PH, Lau J, Chalmers TC. Meta-analysis of effects of intensive blood-glucose control on late complications of type 1 diabetes. Lancet 1993; 341: 1306-1309.
26. Telmer S, Christiansen JS, Andersen AR, Nerup J, Deckert T. Smoking habits and prevalence of clinical diabetic microangiopathy in insulin-dependent diabetics. Acta Med Scand 1984; 215: 63-68.
27. Norden G, Nyberg G. Smoking and diabetic nephropathy. Acta Med Scand 1984; 215: 257-261.
28. Mühlhauser I, Sawicki PT, Berger M. Cigarette smoking as a risk factor for macroproteinuria and proliferative retinopathy in Type 1 (insulin-dependent) diabetes. Diabetologia 1986; 29: 500-502.
29. Christiansen JS. Cigarette smoking and prevalence of microangiopathy in juvenile-onset insulin-dependent diabetes mellitus. Diabetes Care 1978; 1: 146-149.
30. Rossing P, Borch-Johnsen K, Parving H-H. Risk factors for development of incipient and overt diabetic nephropathy in IDDM patients (Abstract). J Am Soc Nephrol 1993; 4: 308.
31. Chase HP, Garg SK, Marshall G, Berg CL, Harris S, Jackson WE, et al. Cigarette smoking increases the risk of albuminuria among subjects with type 1 diabetes. J Am Med Assoc 1991; 265: 614-617.
32. Agodoa LY, Eggers PW. Renal replacement therapy in the united states: data from the United States renal data system. Am J Kidney Dis 1995; 25: 119-133.
33. Mallick NP, Jones E, Selwood N. The European (European Dialysis and Transplantation Association-European Renal Association) Registry. Am J Kidney Dis 1995; 25: 176-187.
34. Mathiesen ER, Hommel E, Giese J, Parving H-H. Efficacy of captopril in postponing nephropathy in normotensive diabetic patients with microalbuminuria. Br Med J 1991; 303: 81-87.
35. Viberti GC, Mogensen CE, Groop L, Pauls JF, the European Microalbuminuria Captopril Study Group. Effect of Captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. J Am Med Assoc 1994; 271: 275-279.
36. Laffel L, Gans JD, McGill JB. Captopril decreases the rate of progression of renal disease in normotensive, insulin-dependent diabetes mellitus (IDDM) patients with microalbuminuria (Abstract). J Am Soc Nephrol 1993; 4: 304.
37. Borch-Johnsen K, Wenzel H, Viberti GC, Mogensen CE. Is screening and intervention for microalbuminuria worthwhile in patients with insulin dependent diabetes. Br Med J 1993; 306: 1722-1725.
38. Kiberd BA, Jindal KK. Screening to prevent renal failure in insulin dependent diabetic patients: an economic evaluation. Br Med J 1995; 311: 1595-1599.
39. Mogensen CE. Progression of nephropathy in long-term diabetics with proteinuria and effect of initial antihypertensive treatment. Scand J Clin Lab Invest 1976; 36: 383-388.
40. Viberti GC, Bilous RW, Mackintosh D, Keen H. Monitoring glomerular function in diabetic nephropathy. Am J Med 1983; 74: 256-264.
41. Microalbuminuria Collaborative Study Group UK. Risk factors for development of microalbuminuria in insulin dependent diabetic patients: a cohort study. Br Med J 1993; 306: 1235-1239.
42. Mathiesen ER, Rønn B, Jensen T, Storm B, Deckert T. Relationship between blood pressure and urinary albumin excretion in development of microalbuminuria. Diabetes 1990; 39: 245-249.
43. Parving H-H, Andersen AR, Smidt UM, Oxenbøll B, Edsberg B, Christiansen JS. Diabetic nephropathy and arterial hypertension. Diabetologia 1983; 24: 10-12.
44. Hommel E, Mathiesen ER, Giese J, Nielsen MD, Schütten HJ, parving H-H. On the pathogenesis of arterial blood pressure elevation early in the course of diabetic nephropathy. Scand J Clin Lab Invest 1989; 49: 537-544.
45. Feldt-Rasmussen B, Mathiesen ER, Deckert T, et al. Central role for sodium in the pathogenesis of blood pressure changes independent of angiotensin, aldosterone and catecholamines in type 1 (insulin-dependent) diabetes mellitus. Diabetologia 1987; 30: 610-617.
46. Østerby R. Renal pathology in diabetes mellitus. Current Opinion in Nephrology und Hypertension 1993; 2: 475-483.
47. Tomlanovich S, Deen WM, Jones III HW, Schwartz HC, Myers BD. Functional nature of glomerular injury in progressive diabetic glomerulopathy. Diabetes 1987; 36: 556-565.
48. Myers BD, Winetz JA, Chui F, Michaels AS. Mechanisms of proteinuria in diabetic nephropathy: a study of glomerular barrier function. Kidney Int 1982; 21: 633-641.
49. Deckert T, Feldt-Rasmussen B, Djurup R, Deckert M. Glomerular size and charge selectivity in insulin-dependent diabetes mellitus. Kidney Int 1988; 33: 100-106.
50. Hostetter TH, Troy JL, Brenner BM. Glomerular hemodynamics in experimental diabetes mellitus. Kidney Int 1981; 19: 410-415.
51. Rossing P, Hommel E, Smidt UM, Parving H-H. Impact of arterial blood pressure and albuminuria on the progression of diabetic nephropathy in IDDM patients. Diabetes 1993; 42: 715-719.
52. Parving H-H, Rossing P, Hommel E, Smidt UM. Angiotensin converting enzyme inhibition in diabetic nephropathy: ten years experience. Am J Kidney Dis 1995; 26: 99-107.
53. Watkins PJ, Blainey JD, Brewer DB, Fitzgerald MG, Malins JM, O'Sullivan DJ, et al. The natural history of diabetic renal disease. A follow-up study of series of renal biopsies. Q J Med 1972; 41: 437-456.
54. Zatz R, Dunn BR, Meyer TW, Anderson S, Rennke HG, Brenner BM. Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest 1986; 77: 1925-1930.
55. Anderson S, Rennke HG, Garcia DL, Brenner BM. Short and long term effects of antihypertensive therapy in the diabetic rat. Kidney Int 1989; 36: 526-536.
56. Parving H-H, Rossing P. The use of antihypertensive agents in prevention and treatment af diabetic nephropathy. Current Opinion in Nephrology and Hypertension 1994; 3: 292-300.
57. Nyberg G, Blohmé G, Norden G. Impact of metabolic control in progression of clinical diabetic nephropathy. Diabetologia 1987; 30: 82-86.
58. Hostetter TH, Rennke HG, Brenner BM. The case for intrarenal hypertension in the initiation and progression of diabetic and other glomerulopathies. Am J Med 1982; 72: 375-380.
59. Brenner BM. Hemodynamically mediated glomerular injury and the progressive nature of kidney disease. Kidney Int 1983; 23: 647-655.
60. Jensen PK, Steven K, Blr H, Christiansen JS, Parving H-H. The effects of indomethacin on glomerular hemodynamics in experimental diabetes. Kidney Int 1986; 29: 490-495.
61. Steffes MW, Brown DM, Mauer SM. Diabetic glomerulopathy following unilateral nephrectomy in the rat. Diabetes 1978; 27: 35-41.
62. Steffes MW, Brown DM, Mauer SM. The development, enhancement, and reversal of the secondary complications of diabetes mellitus. Hum Pathol 1979; 10: 293-299.
63. Parving H-H, Andersen AR, Smidt UM, Hommel E, Mathiesen ER, Svendsen PA. Effect of antihypertensive treatment on kidney function in diabetic nephropathy. Br Med J 1987; 294: 1443-1447.
64. Parving H-H, Hommel E, Smidt UM. Protection of kidney function and decrease in albuminuria by captopril in insulin dependent diabetics with nephropathy. Br Med J 1988; 297: 1086-1091.
65. Parving H-H, Kastrup J, Smidt UM, Andersen AR, Feldt-Rasmussen B, Christiansen JS. Impaired autoregulation of glomerular filtration rate in Type 1 (insulin-dependent) diabetic patients with nephropathy. Diabetologia 1984; 27: 547-552.
66. Cortes P, Riser BL, Zhao X, Narins RG. Glomerular volume expansion and mesangial cell mechanical strain: mediators of glomerular pressure injury. Kidney Int 1994; 45 (suppl 45): 11-16.
67. Remuzzi G, Bertani T. Is glomerulosclerosis a consequence of altered glomerular permeability to macromolecules? Kidney Int 1990; 38: 384-394.
68. Keane WF, O'Donnell MP, Kasiske BL, Kim Y. Oxidative modification of low-density lipoproteins by mesangial cells. J Am Soc Nephrol 1993; 4: 187-194.
69. Moorhead JF, El-Nahas M, Chan MK, Varghese Z. Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease. Lancet 1982; ii: 1309-1011.
70. Williams PS, Foss G, Bone JM. Renal pathology and proteinuria determine progression in untreated mild/moderate chronic renal failure. Q J Med 1988; 252: 343-354.
71. Peterson JC, Adler S, Burkart JM, Greene T, Herbert LA, Hunsicker LG, et al. Blood pressure control, proteinuria, and the progression of renal disease. Modification of diet in renal disease study. Ann Intern Med 1995; 123: 754-762.
72. Björck S, Mulec H, Johnsen SA, Nordén G, Aurell M. Renal protective effect of enalapril in diabetic nephropathy. Br Med J 1992; 304: 339-343.
73. Walker JD, Bending JJ, Dodds RA, et al. Restriction of dietary protein and progression of renal failure in diabetic nephropathy. Lancet 1989; ii: 1411-1415.
74. Mulec H, Blohmé G, Kullenberg G, Nyberg G, Björck S. Latent overhydration and nocturnal hypertension in diabetic nephropathy. Diabetologia 1995; 38: 216-220.
75. Hansen HP, Rossing P, Tarnow L, Nielsen FS, Jensen BR, Parving H-H. Circadian rhythm of systemic blood pressure and albuminurin in diabetic nephropathy. Kidney Int 1996; 50: 579-585.
76. Berglund J, Lins L-E, Lins P-E. Metabolic and blood pressure monitoring in diabetic renal failure. Acta Med Scand 1985; 218: 401-408.
77. Hasslacher C, Stech W, Wahl P, Ritz E. Blood pressure and metabolic control as risk factors for nephropathy in Type 1 (insulin-dependent) diabetes. Diabetologia 1985; 28: 6-11.
78. Mulec H, Blohmé G, Grände B, Björck S. Progression of overt diabetic nephropathy (DN); role of metabolic control (Abstract). J Am Soc Nephrol 1995; 6: 453.
79. Viberti GC, Bilous RW, Mackintosh D, Bending JJ, Keen H. Long term correction of hyperglycaemia and progression of renal failure in insulin dependent diabetes. Br Med J 1983; 286: 598-602.
80. Sharma K, Ziyadeh FN. Perspectives in diabetes. Hyperglycemia and diabetic kidney disease. The case for transforming growth tactor-β as a key mediator. Diabetes 1995; 44: 1139-1146.
81. Brownlee M, Cerami A, Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 1988; 318: 1315-1321.
82. Mulec H, Johnsen SA, Björck S. Relation between serum cholesterol and diabetic nephropathy. Lancet 1990; 335: 1537-1538.
83. Mulec H, Johnsen SA, Wiklund D, Björck S. Cholesterol: a renal risk factor in diabetic nephropathy? Am J Kidney Dis 1993; 22: 196-201.
84. Krolewski AS, Warram JH, Christlieb AR. Hypercholesterolemia - a determinant of renal function loss and deaths in IDDM patients with nephropathy. Kidney Int 1994; 45 (suppl 45): S125-S131.
85. Rossing P, Hansen BV, Nielsen FS, Myrup B, Holmer G, Parving H-H. Fish oil in diabetic nephropathy. Diabetes Care 1996; in press.
86. Rossing P, Hommel E, Smidt UM, Parving H-H. Reduction in albuminuria predicts diminished progression in diabetic nephropathy. Kidney Int 1994; 45 (suppl 45): S145-S149.
87. Rossing P, Hommel E, Smidt UM, Parving H-H. Reduction in albuminuria predicts a beneficial effect on diminishing the progression of human diabetic nephropathy during antihypertensive treatment. Diabetologia 1994; 37: 511-516.
88. Apperloo AJ, de Zeeuw D, de Jong PE. Short-term antiproteinuric response to antihypertensive treatment predicts long-term CFR decline in patients with non-diabetic renal disease. Kidney Int 1994; 45 (suppl 45): S174-S178.
89. Breyer JA, McGill JB, Nahman NS. Predictors of the rate of progression of renal insufficiency in patients with insulin-dependent diabetes and overt diabetic nephropathy. (Abstract). J Am Soc Nephrol 1993; 4: 301.
90. Ravid M, Neumann L, Lishner M. Plasma lipids and the progression of nephropathy in diabetes mellitus type II: effect of ACE inhibitors. Kidney Int 1995; 47: 907-910.
91. Heeg JE, de Jong PE, van der Hem GK, de Zeeuw D. Reduction of proteinuria by angiotensin converting enzyme inhibition. Kidney Int 1987; 32: 78-83.
92. Anderson S, Rennke HG, Brenner BM. Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J Clin Invest 1986; 77: 1993-2000.
93. Fogo A, Yoshida Y, Glick AD, Homma T, Ichikawa I. Serial micropuncture analysis of glomerular function in two rat models of glomerular sclerosis. J Clin Invest 1988; 82: 322-330.
94. Viberti GC, Mackintosh D, Keen H. Determinants of the penetration of proteins through the glomerular barrier in insulin-dependent diabetes mellitus. Diabetes 1983; 32: 92-95.
95. Morelli E, Loon N, Meyer TW, Peters W, Myers BD. Effects of converting-enzyme inhibition on barrier function in diabetic glomerulopathy. Diabetes 1990; 39: 76-82.
96. Reddi AS, Ramamurthi R, Miller M, Dhuper S, Lasker N. Enalapril improves albuminuria by preventing glomerular loss of heparan sulfate in diabetic rats. Biochem Med Metab Biol 1991; 45: 119-131.
97. Tanaka R, Kon V, Yoshioka T, Ichikawa I, Fogo A. Angiotensin converting enzyme inhibitor modulates golmerular function and structure by distinct mechanisms. Kidney Int 1994; 45: 537-543.
98. Striker GE, Peten EP, Carome MA, Pesce CM, Schmidt K, Yang C-W, et al. The kidney disease of diabetes mellitus (KDDM): a cell and molecular biology approach. Diabetes Metab Rev 1993; 9: 37-56.
99. Seaquist ER, Goetz FC, Rich S, Barbosa J. Familial clustering of diabetic kidney disease: evidence of genetic susceptibility to diabetic nephropathy. N Engl J Med 1989; 320: 1161-1165.
100. Borch-Johnsen K, Nørgaard K, Hommel E, Mathiesen ER, Jensen JS, Deckert T, et al. Is diabetic nephropathy an inherited complication? Kidney Int 1992; 41: 719-722.
101. Cambien F, Poirier O, Lecerf L, Evans A, Cambou JP, Arveiler D, et al. Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature 1992; 359: 641-644.
102. Tarnow L, Cambien F, Rossing P, Nielsen FS, Hansen BV, Lecerf L, et al. Lack of relationship between an insertion/deletion polymorphism in the angiotensin-I-converting enzyme gene and diabetic nephropathy and proliferative retinopathy in IDDM patients. Diabetes 1995; 44: 489-494.
103. Parving H-H, Tarnow L, Rossing P. The angiotensin-converting enzyme gene and its inhibition in diabetic nephropathy. Current Opinion in Nephrology and Hypertension. 1996; 3: 315-321.
104. Tarnow L, Gluud C, Parving H-H. Diabetic nephropathy and the insertion/deletion polymorphism of the angiotensin-converting enzyme gene. Nephrol Dial Transplant 1998; 13: 1125-1130.
105. Jacobsen P, Tarnow L, Rossing P, Cambien F, Lecerf L, Poirier O, et al. The insertion/deletion (I/D) polymorphism in the angiotensin-I-converting enzyme (ACE) gene predicts the progression of diabetic nephropathy during ACE inhibition (ACEI) in insulin dependent diabetic (IDDM) patients (Abstract). J Am Soc Nephrol 1995; 6: 450.
106. van Essen CG, Rensma PL, de Zeeuw D, Sluiter WJ, Scheffer H, Apperloo AJ, et al. Association between angiotensin-converting-enzyme gene polymorphism and failure of renoprotective therapy. Lancet 1996; 347: 94-95.
107. Yoshida H, Mitarai T, Kawamura T, Kitajima T, Miyazaki Y, Nagasawa R, et al. Role of the deletion polymorphism of the angiotensin converting enzyme gene in the progression and therapeutic responsiveness of IgA nephropathy. J Om Invest 1995; 96: 2162-2169.
108. Marre M, Jeunemaitre X, Gallois Y, Rodier M, Chatellier G, Sert C, et al. Contribution of genetic polymorphism in the renin-angiotensin system to the development of renal complications in insulin-dependent diabetes. J Clin Invest 1997; 7: 1585-1595.
109. Alaveras A, Thomas SM, Margiaglone M, Sagriotis A, Viberti GC. Interactions between metabolic and genetic factors on the progression of overt nephropathy in IDDM. Nephrol Dial Transplant 1997; 12: 71-74.
110. Yoshida H, Hamaguchi A, Mitarai T, Kuriyama S, Kawamura T, Tomonari H, et al. Accelerated progression to renal failure in NIDDM patients with the deletion polymorphism of the angiotensin converting enzyme (ACE) gene. J Am Soc Nephrol 1995; 6: 409.
111. Mogensen CE. Diabetic renal disease: the quest for normotension - and beyond. Diabetic Med 1995; 12: 756-769.
112. Parving H-H Smidt UM, Hommel E, Mathiesen ER, Rossing P, Nielsen FS, et al. Effective antihypertensive treatment postpones renal insufficiency in diabetic nephropathy. Am J Kidney Dis 1993; 22: 188-195.
113. Björck S, Nyberg G, Mulec H, Granerus G, Herlitz H, Aurell M. Beneficial effect of angiotensin converting enzyme inhibition on renal function in patients with diabetic nephropathy. Br Med J 1986; 293: 471-447.
114. Joint National Committee on Detection Evaluation and Treatment of High Blood Pressure. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med. 1997; 157: 2413-16.
115. American Diabetes Association. Position statement: diabetic nephropathy. Diabetes Care 1998; 21: S50-S53.
116. Tarnow L, Rossing P, Gall M-A, Nielsen FS, Parving H-H. Prevalence of arterial hypertension in diabetic patients before and after the JNC-V. Diabetes Care 1994; 17: 1247-1251.
117. Sundhedsstyrelsens arbejdsgruppe vedrende diabetesbe-handling. Diabetesbehandling i Danmark - fremtidig organisering. Copenhagen: Sundhedsstyrelsen, 1994.
118. Lewis E, Hunsicker L, Bain R, Rhode R. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329: 1456-1462.
119. Hommel E, Jensen B, Parving H-H. Long term effect of captopril on kidney function in normotensive insulin dependent diabetic patients (IDDM) with diabetic nephropathy (Abstract). J Am Soc Nephrol 1995; 6: 450.
120. Mogensen CE, Keane WF, Bennett PH, et al. Prevention of diabetic renal disease with special reference to microalbuminuria. Lancet 1995; 346: 1080-1084.
121. Marre M, Chatellier G, Leblanc H, Guyenne T-T, Ménard J, Passa P. Prevention of diabetic nephropathy with enalapril in normotensive diabetics with microalbuminuria. Br Med J 1988; 297: 1092-1095.
122. Weidmann P, Boehlen LM, de Courten M, Ferrari P. Antihypertensive therapy in diabetic patients. J Human Hypertens 1992; 6: S23-S36.
123. Kasiske BL, Kalil R, Ma JZ, Liao M, Keane WF. Effect of antihypertensive therapy on the kidney in patients with diabetes: a meta-regression analysis. Ann Intern Med 1993; 118: 129-138.
124. Maki DD, Ma JZ, Louis TA, Kasiske BL. Long-term effects of antihypertensive agents on proteinuria and renal function. Arch Intern Med 1995; 155: 1073-1080.
125. Hansen HP, Rossing P, Tarnow L, Nielsen FS, Jensen BR, Parving H-H. Increased glomerular filtration rate after withdrawal of long-term antihypertensive treatment in diabetic nephropathy. Kidney Int 1995; 47: 1726-1731.
126. Parving H-H, Rossing P, Hommel E, Smidt UM. Renal protective effects of captopril and metoprolol in diabetic nephropathy (Abstract). J Am Soc Nephrol 1992; 3: 337.
127. Parving H-H, Andersen AR, Smidt UM, Christiansen JS, Oxenbl B, Svendsen PA. Diabetic nephropathy and arterial hypertension: the effect of antihypertensive treatment. Diabetes 1983; 32(suppl 2): 83-87.
128. Elving LD, Wetzels JFM, van Lier HJJ, de Nobel E, Berden JHM. Captopril and atenolol are equally effective in retarding progression of diabetic nephropathy. Diabetologia 1994; 37: 604-609.
129. Holdaas H, Hartmann A, Lien MG, Nilsen L, Jervell J, Fauchald P, et al. Contrasting effects of lisinopril and nifedipine on albuminuria and tubular transport functions in insulin dependent diabetics with nephropathy. J Intern Med 1991; 229: 163-170.
130. Melbourne Diabetic: Nephropathy Study Group. Comparison between perindopril and nifedipine in hypertensive and normotensive diabetic patients with microalbuminuria. Br Med J 1991; 302: 210-216.
131. Nørgaard K, Jensen T, Christensen P, Feldt-Rasmussen B. A comparison of spirapril and isradipine in patients with diabetic nephropathy and hypertension. Blood Pressure 1993; 2: 301-308.
132. Jungmann E, Haak T, Malanyn M, Mortasawi N, Scherberich J, Usadel KH. Comparative study on renal effects of nitrendipine vs enalapril in microalbuminuric patients with type 1 diabetes mellitus (Abstract). Diabetologia 1992; 35: A149.
133. Bretzel RG, Bollen CC, Maeser E, Federlin KF. Nephroprotective effects of nitrendipine in hypertensive type I and type II diabetic patients. Am J Kidney Dis 1993; 6: 53-64.
134. Mimran A, Insua A, Ribstein J, Bringer J, Monnier L. Comparative effect of captopril and nifedipine in normotensive patients with incipient diabetic nephropathy. Diabetes Care 1988; 11: 850-853.
135. Chan JCN, Cockram CS, Nicholls MG, Cheung CK, Swaminathan R. Comparison of enalapril and nifedipine in treating non-insulin dependent diabetics associated with hypertension: one year analysis. Br Med J 1992; 305: 981-985.
136. O'Donnell MJ, Rowe BR, Lawson N, Horton A, Cycle OH, Barnett AH. Comparison of the effects of an angiotensin converting enzyme inhibitor and a calcium antagonist in hypertensive, macroproteinuric diabetic patients: a randomised double-blind study. J Human Hypertens 1993; 7: 333-339.
137. Rossing P, Tarnow L, Boelskifte S, Jensen BR, Nielsen FS, Parving H-H. Differences between nisoldipine and lisinopril on glomerular filtration rates and albuminuria in hypertensive IDDM patients with diabetic nephropathy during the first year of treatment. Diabetes 1997; 46: 481-487.
138. Demaire BK, Bakris GL. Effects of different classes of calcium antagonist on proteinuria in diabetic subjects. Ann Intern Med 1990; 113: 987-988.
139. Bakris GL, Copley JB, Vicknair N, Leugans S. Effect of nondihydropyridine calcium antagonists (NDCAs) on progression of nephropathy from non-insulin dependent diabetes (NIDDM): a five year follow-up study (Abstract). J Am Soc Nephrol 1995; 6: 446.
140. Zucchelli P, Zuccala A, Borghi M, Fusaroli M, Sasdelli M, Stallone C, et al. Long-term comparison between captopril and nifedipine in the progression of renal insufficiency. Kidney Int 1992; 42: 452-458.
141. Anderson S. Renal hemodynamic effects of calcium antagonists in rats with reduced renal mass. Hypertension 1991; 17: 288-295.
142. Epstein M. Calcium antagonists should continue to be used for first-line treatment of hypertension. Arch Intern Med 1995; 155: 2150-2156.
143. Dworkin LD, Benstein JA, Parker M, Tolbert E, Feiner HD. Calcium antagonists and converting enzyme inhibitors reduce renal injury by different mechanisms. Kidney Int 1993; 43: 808-814.
144. Shultz PJ, Raij L. Inhibition of human mesangial cell proliferation by calcium channel blockers. Hypertension 1990; 15: 76-80.
145. Bakris GL, Barnhill BW, Sadler R. Treatment of arterial hypertension in diabetic humans: importance of therapeutic selection. Kidney Int 1992; 41: 912-919.
146. Brown SA, Walton CL, Crawford P, Bakris GL. Long-term effects of antihypertensive regimens on renal hemodynamics and proteinuria. Kidney Int 1993; 43: 1210-1218.
147. Urata H, Boehm KD, Philip A, et al. Cellular localization and regional distribution of an angiotensin II-vorming chymase in the heart. J Clin Invest 1993; 91: 1269-1281.
148. Kjekshus J, Pedersen TR. Reducing the risk of coronary events: evidence from the Scandinavian Simvastatin Survival Study (4S). Am J Cardiol 1995; 76: 64C-68C.
149. Kasiske BL, O'Donnell MP, Cleary MP, Keane WF. Treatment of hyperlipidemia reduces glomerular injury in obese Zucker rats. Kidney Int 1988; 33: 667-672.
150. Kasiske BL, O'Donnell MP, Garvis WJ, Keane WF. Pharmacologic treatment of hyperlipidemia reduces glomerular injury in rat 5/6 nephrectomy model of chronic renal failure. Cicr Res 1988; 62: 367-374.
151. Kasiske BL, O'Donnell MP, Kim Y, Atluru D, Keane WF. Cholesterol synthesis inhibitors inhibit more than cholesterol synthesis. Kidney Int 1994; 45: S51-S53.
152. Rabelink AJ, Hené RJ, Erkelens DW, Joles JA, Koomans HA. Partial remission of nephrotic syndrome in patients on long-term simvastatin. Lancet 1990; 335: 1045-1046.
153. Shoji T, Nishizavva Y, Toyokawa A, Kawagishi T, Okuno Y, Morii H. Decreased albuminuria by pravastatin in hyperlipidemic diabetics. Nephron 1991; 59: 664-665.
154. Nielsen S, Schmitz O, Møller N, Pørksen N, Klausen IC, Alberti KGMM, et al. Renal function and insulin sensitivity during simvastatin treatment in Type 2 (non-insulin-dependent) diabetic patients with microalbuminuria. Diabetologia 1993; 36: 1079-1086.
155. Lam KS, Cheng IKP, Janus ED, Pang RWC. Cholesterol-lowering therapy may retard the progression of diabetic nephropathy. Diabetologia 1995; 38: 604-609.
156. Thomas ME, Harris KPG, Ramaswamy C, Hattersley JM, Wheeler DC, Varghese Z, et al. Simvastatin therapy for hypercholesterolemic patients with nephrotic syndrome or significant proteinuria. Kidney Int 1993; 44: 1124-1129.
157. Dyerberg J, Bang HO. Hemostatic function and platelet polyunsaturated fatty acids in Eskimos. Lancet 1979; ii: 433-435.
158. Kromhout D, Bosschieter EB, de Lezenne Coulander C. The inverse relation between fish consumption and 20-year mortality from coronary heart disease. N Engl J Med 1985; 312: 1205-1209.
159. Burr ML, Fehily AM, Gilbert JF, et al. Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: Diet and Reinfarction Trial (DART). Lancet 1989; ii: 757-761.
160. De Caterina R, Caprioli R, Giannessi D, et al. n-3 Fatty acids reduce proteinuria in patients with chronic glomerular disease. Kidney Int 1993; 44: 843-850.
161. Donadio JV, Bergstralh EJ, Offord KP, Spencer DC, Holley KE. A controlled trial of fish oil in IgA nephropathy. N Engl J Med 1994; 331: 1194-1199.
162. van der Heide JJH, Bilo HJG, Donker JM, Wilmink JM, Tegzess AM. Effect of dietary fish oil on renal function and rejection in cyclosporine-treated recipients of renal transplants. N Engl J Med 1993; 329: 769-773.
163. De Caterina R, Endres S, Kristensen SD, Schmidt EB. n-3 fatty acids and renal diseases. Am J Kidney Dis 1994; 24: 397-415.
164. Jensen T, Stender S, Goldstein K, Holmer G, Deckert T. Partial normalization by dietary cod-liver oil of increased microvascular albumin leakage in patients with insulin-dependent diabetes and albuminuria. N Engl J Med 1989; 321: 1572-1577.
165. Haines AP. Fish oil supplement in diabetics. Thromb Res 1986; 43: 644-655.
166. Hamazaki T, Takazakura E, Osawa K, Urakaze M, Yano S. Reduction in microalbuminuria in diabetics by eicosapentaenoic acid ethyl ester. Lipids 1990; 25: 541-545.
167. Fujikawa M, Yamazaki K, Hamazaki T, Wakaki K, Koizumi F, Yano S, et al. Effect of eicosapentaenoic acid ethyl ester on albuminuria in streptozotocin-induced diabetic rats. J Nutr Sci Vitaminol 1994; 40: 49-61.
168. Appel LJ, Miller ER, Seidler AJ, Whelton PK. Does supplementation of diet with 'fish oil' reduce blood pressure? A meta-analysis of controlled clinical trials. Arch Intern Med 1993; 53: 1429-1438.
169. The Diabetes Control and Complications Trial Research Group. Effect of intensive therapy on the development and progression of diabetic nephropathy in the diabetes control and complications trial. Kidney Int 1995; 47: 1703-1720.
170. Microalbuminuria Collaborative Study Group U. Intensive therapy and progressive to clinical albuminuria in patients with insulin dependent diabetes mellitus and microalbuminuria Br Med J 1995; 311: 973-977.
171. Zatz R, Meyer TW, Rennke HG, Brenner BM. Predominance of hemodynamic rather than metabolic factors in the pathogenesis of diabetic glomerulopathy. Proc Natl Acad Sci USA 1985; 82: 5963-5967.
172. Zatz R, Brenner BM. Pathogenesis of diabetic microangiopathy. The hemodynamic view. Am J Med 1986; 80: 443-453.
173. Zeller KR, Whittaker E, Sullivan L, Raskin P, Jacobson HR. Effect of restricting dietary protein on the progression of renal failure in patients with insulin-dependent diabetes melitus. N Engl Med 1991; 324: 78-84.
174. Parving H-H. Low-protein diet and progression of renal disease in diabetic nephropathy (Letter). Lancet. 1990; 335: 411.
175. Parving H-H. Protein restriction and renal failure in diabetes mellitus. N Engl J Med 1991; 324: 1743-1744.
176. Klahr S, Levey AS, Beck GJ, Caggiula AW, Hunsicker L, Kusek JW, et al. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. N Engl J Med 1994; 330: 877-884.
177. Borch-Johnsen K, Andersen PK, Deckert T. The effect of proteinuria on relative mortality in Type 1 (insulin-dependent) diabetes mellitus. Diabetologia 1985; 28: 590-596.
178. Knowles HCJ. Long term juvenile diabetes treated with unmeasured diet. Trans Assoc Am Physicians 1971; 84: 95-101.
179. Deckert T, Feldt-Rasmussen B, Borch-Johnsen K, Jensen T, Kofoed-Enevoldsen A. Albuminuria reflects widespread vascular damage. The Steno hypothesis. Diabetologia 1989; 32: 219-226.
180. Jensen T, Borch-Johnsen K, Kofoed-Enevoldsen A, Deckert T. Coronary heart disease in young Type 1 (insulin-dependent) diabetic patients with and without diabetic nephropathy: incidence and risk-factors. Diabetologia 1987; 30: 144-1448.
181. Parving H-H, Hommel E. Prognosis in diabetic nephropathy. Br Med J 1989; 299: 230-233.
182. Mathiesen ER, Borch-Johnsen K, Jensen DV, Deckert T. Improved survival in patients with diabetic nephropathy. Diabetologia 1989; 32: 884-886.
183. Parving H-H, Jacobsen P, Rossing K, Smidt UM, Hommel E, Rossing P. Benefits of long-term antihypertensive treatment on prognosis in diabetic nephropathy. Kidney Int 1996; 49: 1778-1782.
184. Stephenson J, Kenny S, Stevens LK, Fuller JH, Lee E, WHO Multinational Study Croup. Proteinuria and mortality in diabetes: the WHO multinational study of vascular disease in diabetes. Diabetic Med 1995; 12: 149-155.
185. Rossing P, Hougaard P, Borch-Johnsen K, Parving H-H. Predictors of mortality in insulin dependent diabetes: 10 year follow up study. Br Med J 1996; 313: 779-784.
186. Sawicki PT, Mühlhauser I, Didjurgeit U, Baumgartner A, Bender R, Berger M. Intensified antihypertensive therapy is associated with improved survival in type 1 diabetic patients with nephropathy. J Hypertens 1995; 13: 933-938.
187. Terasaki PI, Cecka M, Gjertson DW, Takemoto S. High survival rates of kidney transplants from spousal and living unrelated donors. N Engl J Med 1995; 333: 333-336.
188. Manske CL, Wang Y, Thomas W. Mortality of cadaveric kidney transplantation versus combined kidney-pancreas transplantation in diabetic patients. Lancet 1995; 346: 1658-1662.
189. Parving H-H, Østerby R, Anderson PW, Hsueh WA. Diabetic nephropathy. In: Brenner BM, ed. The Kidney, 5th edn. Philadelphia: Saunders, 1996: 1864-1892.